NCT04408118: First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin) in mTNBC

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy and/or targeted therapy and/or immunotherapy and/or antiangiogenic agent for metastatic breast cancer (MBC); Patients with known active progressive brain metastases – see trial for details; Patients with leptomeningeal disease

Comments are closed.

Up ↑